FY25 PAT growth of 20%. Guiding for 15-20% revenue growth in FY25. Possibility of inorganic growth coming in FY26. Attractive valuations with potential for re-rating.
I have written my thesis on Natco Pharma. Could you please read my write-up on Natco Pharma and provide your feedback?
Highly appreciated!
https://open.substack.com/pub/manthanrastogi/p/natco-pharma-a-revlimid-story?r=1mklg7&utm_campaign=post&utm_medium=web
I have written my thesis on Natco Pharma. Could you please read my write-up on Natco Pharma and provide your feedback?
Highly appreciated!
https://open.substack.com/pub/manthanrastogi/p/natco-pharma-a-revlimid-story?r=1mklg7&utm_campaign=post&utm_medium=web